| 000 | 02664cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031427.0 | ||
| 008 | 160221s2015 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.05.Ph.D.2015.Fa.O | ||
| 100 | 0 | _aFaten Awad Mohamed Awad | |
| 245 | 1 | 0 |
_aOutcome analysis of pediatric B-cell non hodgkin's lymphoma treated with FAB-LMB 96 / _cFaten Awad Mohamed Awad ; Supervised Mohamed Hany Hussien , Alaa M .EL Haddad , Hany Abdelrahman Sayed |
| 246 | 1 | 5 | _aFAB-LMB 96 تحليل نتائج العلاج لمرضى سرطان الغدد الليمفاويه للاطفال المعالجين طبقا لبروتكول |
| 260 |
_aCairo : _bFaten Awad Mohamed Awad , _c2015 |
||
| 300 |
_a154 P. : _bcharts . facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric oncology | ||
| 520 | _aBackground: Mature B cell lymphoma accounts for more than half of the NHLs occurring in children and adolescents. Outcome has improved dramatically over the past decade. Purpose: to analyze the outcome results, Overall Survival (OS) and Event Free Survival (EFS) of patients with mature B-cell Non-Hodgkin Lymphoma receiving FAB/LMB 96 protocol, the treatment related toxicity and the impact of dose density on the outcome. Results: The mean age of the patients was 6.5 years; the distribution of primary site was abdomen 68.8%, head and neck 11.4%, mediastinum 8.1 % , bone marrow involvement 4.9% & CNS involvement 4.9%. According to the histological classification, 83.6% were BL, 11.5 % DLBCL and 4.9% matures B cell (L3) leukemia. According to FAB risk group, 4.9 % were group A, 85.2% group B and 9.8 % group C. OS & EFS for the whole group was 88.1% for both with a median follow up period of 35 months. The EFS for group A was 100 %, group B 91.5% and group C 66.7%. Conclusion: the outcome of children with mature B cell NHL treated with FAB/LMB 96 protocol in NCI {u2013}Egypt was comparable to the international results. The reduction of treatment of group B patients improved the EFS and decreased the rate of toxic morbidities and mortalities | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aFAB/LMB 96 | |
| 653 | 4 | _aMature B-cell NHL | |
| 653 | 4 | _aPediatric oncology | |
| 700 | 0 |
_aAlaa M .EL Haddad , _eSupervisor |
|
| 700 | 0 |
_aHany Abdelrahman Sayed , _eSupervisor |
|
| 700 | 0 |
_aMohamed Hany Hussien , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c55091 _d55091 |
||